Staphylococcus species assay
Test in Focus
Staphylococcus argenteus and Staphylococcus schweitzeri are two recently described bacterial species related to Staphylococcus aureus. In this "Test in Focus" episode of the "Answers From the Lab" podcast, Audrey Schuetz, M.D., discusses Mayo Clinic Laboratories' unique PCR assay that identifies these Staphylococcus species.
"Our assay can differentiate Staphylococcus argenteus and Staphylococcus schweitzeri from Staphylococcus aureus. That is unique," Dr. Schuetz says. "Other available methods, even some of the very advanced methods, don't differentiate these species."
Mayo Clinic Laboratories’ assay can clarify whether bacterial colonies contain the recently described Staphylococcus species. "We do not run the assay on direct patient specimens, such as nasal swabs. It's intended for use on isolates when we have an unclear identification of Staphylococcus species," Dr. Schuetz says. "The organism may look like a staph species, but the color might not be quite right. Mass spectrometry, which many of us rely on in the laboratory, might be delivering an unclear reading."
Precise identification and reporting of Staphylococcus species benefit patient care. Clinicians might not be familiar with the newly described species, which — with Staphylococcus aureus — comprise the "Staphylococcus aureus complex."
"Clinicians who don't recognize these newly described organisms might think of them as coagulase-negative staphylococci — which generally aren't as concerning clinically as Staphylococcus aureus," Dr. Schuetz says. "The lab results might not be taken as seriously. Clinicians could end up providing inappropriate or suboptimal treatment."
Listen to learn more about how the IDENT assay can provide more informative results for Staphylococcus testing.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.